Cardiovascular and metabolic disease segment
AstraZeneca’s (AZN) Cardiovascular and Metabolic Diseases (or CVMD) segment includes various products like Brilinta, Farxiga, Bydureon, Byetta, Onglyza, Symlin, and legacy products like Atacand, Crestor, Seloken, and others. The CVMD segment reported revenues of $1.9 billion during 4Q17, a 6% increase in operating revenues driven by strong sales of Brilinta, Farxiga, Onglyza, and Bydureon. However, the lower sales of Byetta, Crestor, Seloken, and Atacand, had partially offset the growth in revenues during 4Q17. The below chart compares the revenues for key CVMD products since 1Q17.
Brilinta, a cardiovascular drug, reported revenues of $299 million during 4Q17, a 24% increase in operating revenues. Brilinta revenues also reported a 3% favorable impact of foreign exchange during 4Q17. The US sales increased by 47% to $154 million, while the sales from European markets increased by 15% to $82 million, and the sales from established rest of the world markets increased by 30% to $25 million during 4Q17. The growth was partially offset by an 8% decline in sales from emerging markets to $49 million during 4Q17.
Farxiga reported revenues of $332 million during 4Q17, a 24% increase in operating revenues and a 2% favorable impact of foreign exchange. The growth was driven by increased sales across all the markets.
Crestor reported revenues of $594 million during 4Q17, a 7% decrease in operating revenues. The decline in revenues was due to lower sales from the European markets, and established rest of the world markets, partially offset by strong sales in the US and emerging markets.
Other CVMD products
Other CVMD products include Onglyza, Bydureon, Byetta, Symlin, Qtern, Seloken, Atacand, and other products. Of these, Onglyza, Bydureon, Symlin, and Qtern, reported positive growth in revenues during 4Q17, while the remaining products reported lower sales in major markets worldwide.